Evidence map›Paper›PMID 36320622›Full record

ArticlePlastic and reconstructive surgery. Global open2022

Review of Autologous Fat Grafting in Postmastectomy Reconstruction Patients: Nonroutine Diagnostics and Oncologic Safety.

Adaah A Sayyed, Idanis M Perez-Alvarez, Tanvee Singh, Caroline A King, Alexandra F Welschmeyer, Alexander J Bartholomew, Sarah Sher, Eleni A Tousimis, David H Song, Kenneth L Fan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Plastic and reconstructive surgery. Global open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Adaah A SayyedDepartment of Plastic and Reconstructive Surgery, MedStar Georgetown University Hospital, Washington, D.C.
Idanis M Perez-AlvarezDepartment of Plastic and Reconstructive Surgery, Rush University Medical Center, Chicago, Ill.
Tanvee SinghDepartment of Anesthesia, Columbia University Irving Medical Center; New York City, N.Y.
Caroline A KingGeorgetown University School of Medicine, Washington, D.C.
Alexandra F WelschmeyerDepartment of Otolaryngology - Head and Neck Surgery, Case Western Reserve University/University Hospitals Cleveland Medical, Cleveland, Ohio.
Alexander J BartholomewDepartment of Surgery, Duke University Medical Center; Durham, N.C.
Sarah SherDepartment of Plastic and Reconstructive Surgery, MedStar Montgomery Medical Center, Olney, Md.
Eleni A TousimisDepartment of Breast Surgical Oncology, Cleveland Clinic Indian River Hospital, Vero Beach, Fla.
David H SongDepartment of Plastic and Reconstructive Surgery, MedStar Georgetown University Hospital, Washington, D.C.
Kenneth L FanDepartment of Plastic and Reconstructive Surgery, MedStar Georgetown University Hospital, Washington, D.C.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autologous fat grafting (FG) is increasingly used as an adjunctive reconstruction technique to augment volume, achieve symmetry, and improve contour deformities. This study aims to characterize the oncologic and surgical safety of FG in women undergoing autologous breast reconstruction (ABR) or implant-based reconstruction (IBR). Methods: A retrospective chart review was performed for all patients undergoing FG at a multi-site single health system between 2015 to 2018. A total of 228 eligible breasts from 155 patients were identified using Current Procedural Terminology codes. Patients were divided by reconstructive technique. Bivariate analyses compared baseline characteristics and post-FG outcomes. Results: Mean age for patients undergoing ABR (129 breasts) was 52.8 years compared to 48.6 years for those undergoing IBR (99 breasts; Conclusion: FG is a safe, surgically simple procedure more commonly performed in ABR breasts. FG use in ABR and IBR breasts is oncologically safe, with no impairment in breast surveillance and low rates of locoregional recurrence, but possibly increased incidence of nonroutine imaging and biopsies.

Identifiers

PMID36320622
PMCPMC9616633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.